Torri D Metz1, Rebecca G Clifton2, Brenna L Hughes3, Grecio J Sandoval2, William A Grobman4, George R Saade5, Tracy A Manuck3, Monica Longo6, Amber Sowles1, Kelly Clark3, Hyagriv N Simhan7, Dwight J Rouse8, Hector Mendez-Figueroa9, Cynthia Gyamfi-Bannerman10, Jennifer L Bailit11, Maged M Costantine12, Harish M Sehdev13, Alan T N Tita14, George A Macones15. 1. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City. 2. George Washington University Biostatistics Center, Washington, DC. 3. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill. 4. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois. 5. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston. 6. Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland. 7. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, Pennsylvania. 8. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island. 9. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Health Science Center at Houston, Children's Memorial Hermann, Hospital, Houston. 10. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Columbia University, New York, New York. 11. MetroHealth Medical Center, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Case Western Reserve University, Cleveland, Ohio. 12. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Ohio State University, Columbus. 13. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia. 14. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Alabama at Birmingham. 15. Department of Women's Health, University of Texas at Austin.
Abstract
Importance: It remains unknown whether SARS-CoV-2 infection specifically increases the risk of serious obstetric morbidity. Objective: To evaluate the association of SARS-CoV-2 infection with serious maternal morbidity or mortality from common obstetric complications. Design, Setting, and Participants: Retrospective cohort study of 14 104 pregnant and postpartum patients delivered between March 1, 2020, and December 31, 2020 (with final follow-up to February 11, 2021), at 17 US hospitals participating in the Eunice Kennedy Shriver National Institute of Child Health and Human Development's Gestational Research Assessments of COVID-19 (GRAVID) Study. All patients with SARS-CoV-2 were included and compared with those without a positive SARS-CoV-2 test result who delivered on randomly selected dates over the same period. Exposures: SARS-CoV-2 infection was based on a positive nucleic acid or antigen test result. Secondary analyses further stratified those with SARS-CoV-2 infection by disease severity. Main Outcomes and Measures: The primary outcome was a composite of maternal death or serious morbidity related to hypertensive disorders of pregnancy, postpartum hemorrhage, or infection other than SARS-CoV-2. The main secondary outcome was cesarean birth. Results: Of the 14 104 included patients (mean age, 29.7 years), 2352 patients had SARS-CoV-2 infection and 11 752 did not have a positive SARS-CoV-2 test result. Compared with those without a positive SARS-CoV-2 test result, SARS-CoV-2 infection was significantly associated with the primary outcome (13.4% vs 9.2%; difference, 4.2% [95% CI, 2.8%-5.6%]; adjusted relative risk [aRR], 1.41 [95% CI, 1.23-1.61]). All 5 maternal deaths were in the SARS-CoV-2 group. SARS-CoV-2 infection was not significantly associated with cesarean birth (34.7% vs 32.4%; aRR, 1.05 [95% CI, 0.99-1.11]). Compared with those without a positive SARS-CoV-2 test result, moderate or higher COVID-19 severity (n = 586) was significantly associated with the primary outcome (26.1% vs 9.2%; difference, 16.9% [95% CI, 13.3%-20.4%]; aRR, 2.06 [95% CI, 1.73-2.46]) and the major secondary outcome of cesarean birth (45.4% vs 32.4%; difference, 12.8% [95% CI, 8.7%-16.8%]; aRR, 1.17 [95% CI, 1.07-1.28]), but mild or asymptomatic infection (n = 1766) was not significantly associated with the primary outcome (9.2% vs 9.2%; difference, 0% [95% CI, -1.4% to 1.4%]; aRR, 1.11 [95% CI, 0.94-1.32]) or cesarean birth (31.2% vs 32.4%; difference, -1.4% [95% CI, -3.6% to 0.8%]; aRR, 1.00 [95% CI, 0.93-1.07]). Conclusions and Relevance: Among pregnant and postpartum individuals at 17 US hospitals, SARS-CoV-2 infection was associated with an increased risk for a composite outcome of maternal mortality or serious morbidity from obstetric complications.
Importance: It remains unknown whether SARS-CoV-2 infection specifically increases the risk of serious obstetric morbidity. Objective: To evaluate the association of SARS-CoV-2 infection with serious maternal morbidity or mortality from common obstetric complications. Design, Setting, and Participants: Retrospective cohort study of 14 104 pregnant and postpartum patients delivered between March 1, 2020, and December 31, 2020 (with final follow-up to February 11, 2021), at 17 US hospitals participating in the Eunice Kennedy Shriver National Institute of Child Health and Human Development's Gestational Research Assessments of COVID-19 (GRAVID) Study. All patients with SARS-CoV-2 were included and compared with those without a positive SARS-CoV-2 test result who delivered on randomly selected dates over the same period. Exposures: SARS-CoV-2 infection was based on a positive nucleic acid or antigen test result. Secondary analyses further stratified those with SARS-CoV-2 infection by disease severity. Main Outcomes and Measures: The primary outcome was a composite of maternal death or serious morbidity related to hypertensive disorders of pregnancy, postpartum hemorrhage, or infection other than SARS-CoV-2. The main secondary outcome was cesarean birth. Results: Of the 14 104 included patients (mean age, 29.7 years), 2352 patients had SARS-CoV-2 infection and 11 752 did not have a positive SARS-CoV-2 test result. Compared with those without a positive SARS-CoV-2 test result, SARS-CoV-2 infection was significantly associated with the primary outcome (13.4% vs 9.2%; difference, 4.2% [95% CI, 2.8%-5.6%]; adjusted relative risk [aRR], 1.41 [95% CI, 1.23-1.61]). All 5 maternal deaths were in the SARS-CoV-2 group. SARS-CoV-2 infection was not significantly associated with cesarean birth (34.7% vs 32.4%; aRR, 1.05 [95% CI, 0.99-1.11]). Compared with those without a positive SARS-CoV-2 test result, moderate or higher COVID-19 severity (n = 586) was significantly associated with the primary outcome (26.1% vs 9.2%; difference, 16.9% [95% CI, 13.3%-20.4%]; aRR, 2.06 [95% CI, 1.73-2.46]) and the major secondary outcome of cesarean birth (45.4% vs 32.4%; difference, 12.8% [95% CI, 8.7%-16.8%]; aRR, 1.17 [95% CI, 1.07-1.28]), but mild or asymptomatic infection (n = 1766) was not significantly associated with the primary outcome (9.2% vs 9.2%; difference, 0% [95% CI, -1.4% to 1.4%]; aRR, 1.11 [95% CI, 0.94-1.32]) or cesarean birth (31.2% vs 32.4%; difference, -1.4% [95% CI, -3.6% to 0.8%]; aRR, 1.00 [95% CI, 0.93-1.07]). Conclusions and Relevance: Among pregnant and postpartum individuals at 17 US hospitals, SARS-CoV-2 infection was associated with an increased risk for a composite outcome of maternal mortality or serious morbidity from obstetric complications.
Authors: Caroline G Atyeo; Lydia L Shook; Sara Brigida; Rose M De Guzman; Stepan Demidkin; Cordelia Muir; Babatunde Akinwunmi; Arantxa Medina Baez; Maegan L Sheehan; Erin McSweeney; Madeleine D Burns; Ruhi Nayak; Maya K Kumar; Chinmay D Patel; Allison Fialkowski; Dana Cvrk; Ilona T Goldfarb; Lael M Yonker; Alessio Fasano; Alejandro B Balazs; Michal A Elovitz; Kathryn J Gray; Galit Alter; Andrea G Edlow Journal: Nat Commun Date: 2022-06-28 Impact factor: 17.694
Authors: Luisa Mirtha Estrada-Chiroque; Milagros Orostegui-Arenas; Maria Del Pilar Burgos-Guanilo; Juan Manuel Amau-Chiroque Journal: Rev Colomb Obstet Ginecol Date: 2022-03-30
Authors: Seemab Naqvi; Farnaz Naqvi; Sarah Saleem; Vanessa R Thorsten; Lester Figueroa; Manolo Mazariegos; Ana Garces; Archana Patel; Prabir Das; Avinash Kavi; Shivaprasad S Goudar; Fabian Esamai; Musaku Mwenchanya; Elwyn Chomba; Adrien Lokangaka; Antoinette Tshefu; Sana Yousuf; Melissa Bauserman; Carl L Bose; Edward A Liechty; Nancy F Krebs; Richard J Derman; Waldemar A Carlo; Patricia L Hibberd; Sk Masum Billah; Nalini Peres-da-Silva; Rashidul Haque; William A Petri; Marion Koso-Thomas; Tracy Nolen; Elizabeth M McClure; Robert L Goldenberg Journal: BJOG Date: 2022-07 Impact factor: 7.331
Authors: Carolina Loyola Prest Ferrugini; Neide Aparecida Tosato Boldrini; Franco Luis Salume Costa; Michelle Anne de Oliveira Batista Salgueiro; Pamella Dunga de Paula Coelho; Angelica Espinosa Miranda Journal: PLoS One Date: 2022-03-11 Impact factor: 3.240